Natriuretic peptides in heart failure with preserved left ventricular ejection fraction: from molecular evidences to clinical implications
The incidence of heart failure with preserved ejection fraction (HFpEF) is increasing and its
challenging diagnosis and management combines clinical, imagistic and biological data …
challenging diagnosis and management combines clinical, imagistic and biological data …
Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
Cardiovascular diseases have become a major clinical burden globally. Heart failure is one
of the diseases that commonly emanates from progressive uncontrolled hypertension. This …
of the diseases that commonly emanates from progressive uncontrolled hypertension. This …
Therapeutic effects of higenamine combined with [6]‐gingerol on chronic heart failure induced by doxorubicin via ameliorating mitochondrial function
J Wen, L Zhang, J Wang, J Wang… - Journal of cellular …, 2020 - Wiley Online Library
Higenamine (HG) is a natural benzylisoquinoline alkaloid isolated from Aconitum with
positive inotropic and chronotropic effects. This study aimed to investigate the possible …
positive inotropic and chronotropic effects. This study aimed to investigate the possible …
ARNi: a novel approach to counteract cardiovascular diseases
Cardiovascular diseases (CVDs) still represent the greatest burden on healthcare systems
worldwide. Despite the enormous efforts over the last twenty years to limit the spread of …
worldwide. Despite the enormous efforts over the last twenty years to limit the spread of …
Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy
Cardiovascular (CV) disease is a major cause of morbidity and mortality in the developing
and the developed world. Mortality from CV disease had plateaued in the recent years …
and the developed world. Mortality from CV disease had plateaued in the recent years …
Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …
Sacubitril ameliorates cardiac fibrosis through inhibiting TRPM7 channel
T Jia, X Wang, Y Tang, W Yu, C Li, S Cui… - Frontiers in Cell and …, 2021 - frontiersin.org
Heart failure caused by cardiac fibrosis has become a major challenge of public health
worldwide. Cardiomyocyte programmed cell death (PCD) and activation of fibroblasts are …
worldwide. Cardiomyocyte programmed cell death (PCD) and activation of fibroblasts are …
[HTML][HTML] Progress and prospects of Sacubitril/Valsartan: based on heart failure with preserved ejection fraction
R Jia, Y Ji, D Sun - Biomedicine & Pharmacotherapy, 2022 - Elsevier
Heart failure with preserved ejection fraction (HFpEF) is present in nearly half of patients
with heart failure. The prevalence of heart failure with normal or near-normal ejection …
with heart failure. The prevalence of heart failure with normal or near-normal ejection …
Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction
P Yang, X Li, L Wang, X Wu, C Wang, T Li… - Frontiers in …, 2023 - frontiersin.org
Introduction In 2014, the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to
Determine Impact on Global Mortality and Morbidity in Heart Failure) has shown that …
Determine Impact on Global Mortality and Morbidity in Heart Failure) has shown that …
Neutral endopeptidase (neprilysin) in therapy and diagnostics: yin and yang
EE Feygina, AG Katrukha, AG Semenov - Biochemistry (Moscow), 2019 - Springer
Neprilysin (NEP) is a zinc-dependent metalloproteinase that exists in organisms in both
transmembrane and soluble forms. NEP substrates are involved in regulating the …
transmembrane and soluble forms. NEP substrates are involved in regulating the …